期刊
CELL REPORTS
卷 30, 期 6, 页码 1780-+出版社
CELL PRESS
DOI: 10.1016/j.celrep.2020.01.037
关键词
-
类别
资金
- major programs of National Science and Technology [20181821569]
- National Key R&D Program of China [20171260218]
Cancer cell-derived secretomes have been documented to play critical roles in cancer progression. Intriguingly, alternative extracellular roles of intracellular proteins are involved in various steps of tumor progression, which can offer strategies to fight cancer. Herein, we identify lung cancer progression-associated secretome signatures using mass spectrometry analysis. Among them, PKM2 is verified to be highly expressed and secreted in lung cancer cells and clinical samples. Functional analyses demonstrates that secreted PKM2 facilitates tumor metastasis. Furthermore, mass spectrometry analysis and functional validation identify integrin beta 1 as a receptor of secreted PKM2. Mechanistically, secreted PKM2 directly bound to integrin beta 1 and subsequently activated the FAK/SRC/ERK axis to promote tumor metastasis. Collectively, our findings suggest that PKM2 is a potential serum biomarker for diagnosing lung cancer and that targeting the secreted PKM2-integrin beta 1 axis can inhibit lung cancer development, which provides evidence of a potential therapeutic strategy in lung cancer.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据